

CORRECTED  
VERSION\*

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12N 9/12, C07K 7/00, A61K 39/15, 37/02</b>		<b>A1</b>	(11) International Publication Number: <b>WO 99/55849</b>
			(43) International Publication Date: 4 November 1999 (04.11.99)
(21) International Application Number: <b>PCT/AU99/00314</b>		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 27 April 1999 (27.04.99)		<b>Published</b> <i>With international search report.</i>	
(30) Priority Data: PP 3209 27 April 1998 (27.04.98) AU			
(71) Applicants (for all designated States except US): WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH [AU/AU]; Royal Melbourne Hospital, Royal Parade, Parkville, VIC 3052 (AU). THE UNIVERSITY OF MELBOURNE [AU/AU]; Royal Parade, Parkville, VIC 3052 (AU).			
(72) Inventors; and (75) Inventors/Applicants (for US only): HONEYMAN, Margo, Carole [AU/AU]; 27 Park Street, St. Kilda West, VIC 3182 (AU). COULSON, Barbara, Sue [AU/AU]; 38 Durham Street, Eaglemont, VIC 3084 (AU). HARRISON, Leonard, Charles [AU/AU]; 27 Park Street, St. Kilda West, VIC 3182 (AU).			
(74) Agent: F B RICE & CO.; 605 Darling Street, Balmain, NSW 2041 (AU).			
(54) Title: TYROSINE PHOSPHATASE IA-2, GAD AND ROTAVIRUS VP7 IMMUNITY			
(57) Abstract			
<p>The present invention provides T cell epitopes from IA-2. The present invention also relates to the use of these epitopes in diagnosis and therapy. The present invention further provides rotavirus vaccines.</p>			
<p style="text-align: center;"><b>BEST AVAILABLE COPY</b></p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 9/12, C07K 7/00, A61K 39/15, 37/02</b>		<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/55849</b> <b>(43) International Publication Date:</b> 4 November 1999 (04.11.99)
<b>(21) International Application Number:</b> PCT/AU99/00314 <b>(22) International Filing Date:</b> 27 April 1999 (27.04.99) <b>(30) Priority Data:</b> PP 3209 27 April 1998 (27.04.98) <b>AU</b> <b>(71) Applicants (for all designated States except US):</b> WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH [AU/AU]; Royal Melbourne Hospital, Royal Parade, Parkville, VIC 3052 (AU). THE UNIVERSITY OF MELBOURNE [AU/AU]; Royal Parade, Parkville, VIC 3052 (AU). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> HONEYMAN, Margo, Carole [AU/AU]; 27 Park Street, St. Kilda West, VIC 3182 (AU). COULSON, Barbara, Sue [AU/AU]; 38 Durham Street, Eaglemont, VIC 3084 (AU). HARRISON, Leonard, Charles [AU/AU]; 27 Park Street, St. Kilda West, VIC 3182 (AU). <b>(74) Agent:</b> F B RICE & CO.; 605 Darling Street, Balmain, NSW 2041 (AU).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>	
<b>(54) Title:</b> TYROSINE IA-2, GAD AND ROTAVIRUS VP7 PHOSPHATASE IMMUNITY			
<b>(57) Abstract</b>  The present invention provides T cell epitopes from IA-2. The present invention also relates to the use of these epitopes in diagnosis and therapy. The present invention further provides rotavirus vaccines.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

*Tyrosine IA-2, GAD and rotavirus VP7 phosphatase immunity*

**FIELD OF THE INVENTION**

The present invention relates to T-cell epitopes of tyrosine  
5 phosphatase IA-2 and to methods involving the use of these epitopes.

**BACKGROUND OF THE INVENTION**

Activation of T-cells requires recognition by T-cell receptors of  
specific, antigenic peptides complexed to major histocompatibility complex  
10 (MHC) molecules on the surface of target or antigen-presenting cells (1).  
Such T-cell epitopes, "restricted" by the MHC molecule, are potential tools  
for the diagnosis, monitoring and therapy of infectious, autoimmune and  
neoplastic disorders.

The recently-identified pancreatic islet autoantigen in type 1 diabetes,  
15 IA-2, is a 106 kD member of the protein tyrosine phosphatase family (2,3)  
and an integral membrane protein of neuroendocrine secretory granules (4).  
Circulating autoantibodies that recognise predominantly the cytoplasmic  
domain of IA-2 can be detected in up to 88% of people with  
recently-diagnosed type 1 diabetes and in about half of islet-cell antibody  
20 (ICA)-positive, first-degree type 1 diabetes relatives in whom they indicate  
high risk for clinical disease (5, 6). The cytoplasmic domain of IA-2 has 80%  
sequence identity with another tyrosine phosphatase, IAR (7), also known as  
IA-2  $\beta$  (8) or phogrin (9), which also reacts with antibodies in type 1 diabetes  
(10). T-cell proliferative responses to IA-2 were reported to be increased in  
25 at-risk relatives and in people with recently-diagnosed type 1 diabetes (11).  
T-cell epitope peptides in autoantigens have potential diagnostic and  
therapeutic applications and may hold clues to environmental agents that  
could trigger or exacerbate autoimmune disease. The present inventors have  
identified T-cell epitope peptides within the intracytoplasmic domain of  
30 IA-2 and examined them for sequence similarities with microorganisms and  
dietary proteins as a basis for molecular mimicry.

**SUMMARY OF THE INVENTION**

Accordingly in a first aspect the present invention consists in a  
35 tyrosine phosphatase IA-2 T-cell epitope, the T-cell epitope having a  
sequence included within or consisting of a sequence selected from the

group consisting of IA-2 aa685-700 ANMDISTGHMILAYME, IA-2 aa713-728 WQALCAYQAEPNTCAT, IA-2 aa745-760 PYDHARIKLVESPPS, IA-2 aa787-802 LSHTIADFWQMVWESG, IA-2 aa793-808 DFWQMVWESGCTVIVM, IA-2 aa799-814 WESGCTVIVMLTPLVE, IA-2  
 5 aa805-820 VIVMLTPLVEDGVKQC, IA-2 aa841-856 SEHIWCEDFLVRSFYL, IA-2 aa845-860 WCEDFLVRSFYLNKQV, IA-2 aa847-862 EDFLVRSFYLNKQVQTQ, IA-2 aa889-904 DFRRKVNKCVRGRSCP, IA-2 aa919-934 YILIDMVLNRMAKGVK, IA-2 aa959-974 FEFALTAVAEVNAI and conservative substitutions therein.

10 Sequences from the related tyrosine phosphatase IAR with high % identity and homology to the IA-2 T-cell epitopes, which are themselves potential T-cell epitopes, are also included within the present invention. Accordingly in a second aspect the present invention consists in a T-cell epitope, the T-cell epitope having a sequence included within or consisting  
 15 of a sequence selected from the group consisting of IAR aa721-736 SNMDISTGHMILSYME (88% identity, 88% homology), IAR aa749-764 WEALCAYQAEPNSSFV (69%, 75%), IAR aa781-796 TYDHSRVLLKAENSHS (56%, 69%), IAR aa823-838 LPATVADFWQMVWESG (81%, 88%), IAR aa829-844 DFWQMVWESGCVVIVM (94%, 94%), IAR aa835-850  
 20 WESGCVVIVMLTPLAE (88%, 94%), IAR aa841-856 VIVMLTPLAENGVRQC (81%, 94%), IAR aa877-892 SEHIWCEDFLVRSFYL (100%, 100%), IAR aa881-896 WCEDFLVRSFYLNKQ (94%, 100%), IAR aa883-898 EDFLVRSFYLNKQTN (88%, 100%), IAR aa925-940 DFRRKVNKCVRGRSCP (100%, 100%), IAR aa955-970 YVLIDMVLNKMMAKGAK (81%, 100%), IAR  
 25 aa995-1010 FEFALTAVAEVNAI (100%, 100%) and conservative substitutions therein.

In a preferred embodiment of the present invention the T-cell epitope has a sequence included within or consisting of the sequence VIVMLTPLVEDGVKQC.

30 In a further preferred embodiment the T-cell epitope has the sequence VIVMLTPLVED.

As will be recognised by those skilled in the art modifications may be made to the peptides of the present invention while still retaining function. Such modifications include having amino acid substitutions  
 35 compared to the native IA-2 or IAR sequence but which retain certain structural and functional characteristics. These modifications include

additions, deletions and substitutions, in particular conservative substitutions. It is intended that peptides including such modifications are within the scope of the present invention.

- Whilst the concept of conservative substitution is well known in the field for the sake of clarity the types of substitutions envisaged are set out below.

Original Residue	Exemplary Substitutions	Preferred Substitutions
Ala (A)	val; leu; ile	val
Arg (R)	lys; gln; asn	lys
Asn (N)	gln; his; lys; arg	gln
Asp (D)	glu	glu
Cys (C)	ser	ser
Gln (Q)	asn	asn
Glu (E)	asp	asp
Gly (G)	pro	pro
His (H)	asn; gln; lys; arg	arg
Ile (I)	leu; val; met; ala; phe; norleucine	leu
Leu (L)	norleucine, ile; val; met; ala; phe	ile
Lys (K)	arg; gln; asn	arg
Met (M)	leu; phe; ile;	leu
Phe (F)	leu; val; ile; ala	leu
Pro (P)	gly	gly
Ser (S)	thr	thr
Thr (T)	ser	ser
Trp (W)	tyr	tyr
Tyr (Y)	trp; phe; thr; ser	phe
Val (V)	ile; leu; met; phe ala; norleucine	leu

- Another type of modifications of the peptides envisaged include, but are not limited to, modifications to side chains, incorporation of

unnatural amino acids and/or their derivatives during peptide synthesis and the use of crosslinkers and other methods which impose conformational constraints on the peptides.

Examples of side chain modifications contemplated by the present invention include, but are not limited to, modifications of amino groups such as by reductive alkylation by reaction with an aldehyde followed by reduction with  $\text{NaBH}_4$ ; amidation with methylacetimidate; acylation with acetic anhydride; carbamoylation of amino groups with cyanate; trinitrobenzylation of amino groups with 2,4,6-trinitrobenzene sulphonic acid (TNBS); acylation of amino groups with succinic anhydride and tetrahydrophthalic anhydride; and pyridoxylation of lysine with pyridoxal-5'-phosphate followed by reduction with  $\text{NaBH}_4$ .

The guanidine group of arginine residues may be modified by the formation of heterocyclic condensation products with reagents such as 2,3-butanedione, phenylglyoxal and glyoxal.

The carboxyl group may be modified by carbodiimide activation via O-acylisourea formation followed by subsequent derivitisation, for example, to a corresponding amide.

Tryptophan residues may be modified by, for example, oxidation with N-bromosuccinimide or alkylation of the indole ring with 2-hydroxy-5-nitrobenzyl bromide or sulphenyl halides. Tyrosine residues on the other hand, may be altered by nitration with tetranitromethane to form 3-nitrotyrosine derivative.

Modification of the imidazole ring of a histidine residue may be accomplished by alkylation with iodoacetic acid derivatives or N-carbethoxylation with diethylpyrocarbonate.

Examples of incorporating unnatural amino acids and derivatives during peptide synthesis include, but are not limited to, use of norleucine, 4-amino butyric acid, 4-amino-3-hydroxy-5-phenylpentanoic acid, 6-aminohexanoic acid, t-butylglycine, norvaline, phenylglycine, ornithine, sarcosine, 4-amino-3-hydroxy-6-methylheptanoic acid; 2-thienyl alanine and/or D-isomers of amino acids.

The peptides of the present invention may be derived from IA-2 and IAR. It is, however, preferred that the peptides are produced synthetically using methods well known in the field. For example, the peptides may be synthesised using solution synthesis or solid phase synthesis as described,



for example, in Chapter 9 entitled "Peptide Synthesis" by Atherton and Sheppard which is included in a publication entitled "Synthetic Vaccines" edited by Nicholson and published by Blackwell Scientific Publications. Preferably a solid phase support is utilised which may be polystyrene gel beads wherein the polystyrene may be cross-linked with a small proportion of divinylbenzene (e.g. 1%) which is further swollen by lipophilic solvents such as dichloromethane or more polar solvents such as dimethylformamide (DMF). The polystyrene may be functionalised with chloromethyl or anionomethyl groups. Alternatively, cross-linked and functionalised polydimethyl-acrylamide gel is used which may be highly solvated and swollen by DMF and other dipolar aprotic solvents. Other supports can be utilised based on polyethylene glycol which is usually grafted or otherwise attached to the surface of inert polystyrene beads. In a preferred form, use may be made of commercial solid supports or resins which are selected from PAL-PEG, PAK-PEG, KA, KR or TGR.

In solid state synthesis, use is made of reversible blocking groups which have the dual function of masking unwanted reactivity in the  $\alpha$ -amino, carboxy or side chain functional groups and of destroying the dipolar character of amino acids and peptides which render them inactive. Such functional groups can be selected from t-butyl esters of the structure  $\text{RCO-OCMe}_3\text{-CO-NHR}$  which are known as t-butoxy carboxyl or ROC derivatives. Use may also be made of the corresponding benzyl esters having the structure  $\text{RCO-OCH}_2\text{-C}_6\text{H}_5$  and urethanes having the structure  $\text{C}_6\text{H}_5\text{CH}_2\text{OCO-NHR}$  which are known as the benzyloxycarbonyl or Z-derivatives. Use may also be made of derivatives of fluorenyl methanol and especially the fluorenyl-methoxy carbonyl or Fmoc group. Each of these types of protecting group is capable of independent cleavage in the presence of one other so that frequent use is made, for example, of BOC-benzyl and Fmoc-tertiary butyl protection strategies.

Reference also should be made to a condensing agent to link the amino and carboxy groups of protected amino acids or peptides. This may be done by activating the carboxy group so that it reacts spontaneously with a free primary or secondary amine. Activated esters such as those derived from p-nitrophenol and pentafluorophenyl may be used for this purpose. Their reactivity may be increased by addition of catalysts such as 1-hydroxybenzotriazole. Esters of triazine DHBT (as discussed on page

215-216 of the abovementioned Nicholson reference) also may be used. Other acylating species are formed in situ by treatment of the carboxylic acid (i.e. the Na-protected amino acid or peptide) with a condensing reagent and are reacted immediately with the amino component (the carboxy or C-protected amino acid or peptide). Dicyclohexylcarbodiimide, the BOP reagent (referred to on page 216 of the Nicholson reference), O-Benzotriazole-N, N, N'-tetra methyl-uronium hexafluorophosphate (HBTU) and its analogous tetrafluoroborate are frequently used condensing agents.

10 The attachment of the first amino acid to the solid phase support may be carried out using BOC-amino acids in any suitable manner. In one method BOC amino acids are attached to chloromethyl resin by warming the triethyl ammonium salts with the resin. Fmoc-amino acids may be coupled to the p-alkoxybenzyl alcohol resin in similar manner. Alternatively, use 15 may be made of various linkage agents or "handles" to join the first amino acid to the resin. In this regard, p-hydroxymethyl phenylactic acid linked to aminomethyl polystyrene may be used for this purpose.

In a third aspect the present invention consists in a method of assessing the risk of an individual developing type 1 diabetes. The method 20 comprises measuring responsiveness of T cells of individuals at-risk, either by being a relative of an individual with type 1 diabetes, or with other immune markers of sub-clinical disease eg circulating autoantibodies to islet antigens, or by being exposed to a potential environmental trigger factor (eg non-exclusively virus, dietary agent, toxin). T-cell responses to the peptides 25 are measured non-exclusively by the number of cells with activation markers or with specific levels of activation markers (eg CD69, CD44, CD25), numbers of cells with specific cytokines (eg interferon- $\gamma$ , IL-4, IL-2, IL-10, TNF- $\alpha$  and others) or the levels of cytokines produced in or secreted by the cells, or by proliferation of T cells. All measurements are in comparison to 30 T-cell responses from the same individual without the peptides, and in comparison to responses from healthy controls. Elevated (or changing) responses on any of these, or other appropriate, measures of T-cell responses to the peptides on one (or multiple) occasion/s may indicate the level of risk of type 1 diabetes.

35 In a fourth aspect the present invention consists in a method of therapy for the prevention of the onset of type 1 diabetes in those assessed to

be at-risk. The assessment of risk may be determined either by the method of the present invention, or by T-cell responses to whole molecules or peptides from other type 1 diabetes-associated autoantigens (eg insulin, proinsulin, glutamic acid decarboxylase), and/or by the presence of  
5 antibodies to islet autoantigens.

The therapeutic use of the peptides is to induce tolerance to protect against or ameliorate the symptoms associated with type 1 diabetes, by the oral, aerosol, intranasal or other mode of administration of the peptides to mucosal surfaces, or by other appropriate methods of administration eg  
10 non-exclusively transdermally, subcutaneous or intravenous. The presentation of soluble protein antigen to mucosal surfaces, classically via the oral route, results in selective suppression of antigen-specific T-cell responses, and has been associated with the deviation of immunity away from pro-inflammatory Th1 T-cell responses to antibody (Th2) responses.  
15 Regulatory cells, and, at higher antigen doses, T-cell anergy and T-cell deletion, have been shown to be induced. Aerosol inhalation of an autoantigen (insulin) in an animal model for type 1 diabetes was effective in reducing islet cell pathology and incidence of diabetes(12).

In a fifth aspect the present invention consists in a method of therapy  
20 for the prevention of the re-establishment of type 1 diabetes in those who have received a pancreatic or islet-cell transplant to alleviate their pre-existing type 1 diabetes. The therapy is intended to prevent, reduce or otherwise ameliorate the development of T-cell responses to the autoantigens in the graft, which could lead to its destruction. The method of  
25 administration is as in the above paragraph.

The present inventors have identified T-cell epitope peptides in the intracytoplasmic domain of the type 1 diabetes autoantigen, tyrosine phosphatase IA-2, whose sequence analysis suggests that immunity to rotavirus (whose VP7 sequence mimics epitopes in both IA-2 and GAD)  
30 could predispose to type 1 diabetes by activating crossreactive T cells.

The findings set out herein suggest that RV infection may trigger or exacerbate islet autoimmunity, on the HLA-DR4 background. As rotavirus vaccines currently undergoing trials are live viruses containing the VP7 leader sequence, these findings have implications for development of safe  
35 rotavirus vaccines to protect against islet autoimmunity and prevent the development of type 1 diabetes.

Accordingly in a sixth aspect the present invention consists in a vaccine composition for use in raising an immune response in a subject directed against rotavirus, the composition comprising a plurality of antigens including at least one rotavirus VP7 antigen wherein the sequence of the rotavirus VP7 antigen is modified such that at least one of the sequences which mimic one or more of the epitopes selected from the group consisting of ILLQYVVKSF, ILLNYVRKTF and VIVMLTPLVED are deleted or modified such as to remove or ameliorate mimicry.

In a preferred embodiment of this aspect of the present invention the composition includes at least one attenuated strain of rotavirus, the rotavirus nucleic acid encoding VP7 being modified such that the expressed VP7 antigen is modified such that at least one of the sequences which mimic one or more of the epitopes selected from the group consisting of ILLQYVVKSF, ILLNYVRKTF and VIVMLTPLVED are deleted or modified such as to remove or ameliorate mimicry.

In a further preferred embodiment the sequence which mimics ILLQYVVKSF or ILLNYVRKTF is deleted.

The following is merely one example of the modifications which may be made to the sequences to remove or ameliorate mimicry are as follows:-

VP7aa	17	18	21	24	40	44	45
(RV G3, strain P)	I	L	Y	K	I	L	S
Change to	A	A	A	H	A	A	F

- aa 17: A, a small hydrophobic residue, replaces the P1 anchor for binding to DR4, DQ8
- aa 18: A, a small hydrophobic residue replaces a T-cell receptor contact residue (TCR-CR)
- aa 21: A, a small hydrophobic residue replaces a TCR-CR for both DR4, DQ8
- aa 24: H, a weaker basic residue, replaces K which is conserved in all rotavirus strains and in both GAD65 and GAD67 epitopes
- aa 40: A, a small hydrophobic residue, replaces P1 anchor for binding to DR4, DQ8
- aa 44: A, a small hydrophobic residue replaces a TCR-CR for DR4, and the P4 anchor for binding DQ8

aa 45: F, a bulky hydrophobic residue, present in other G1 VP7 sequences in this position, replaces the P6 anchor for binding to DR4, and a TCR-CR for DQ8.

5 The sequences rotavirus VP7 from various strains are known. These sequences are provided in Reddy et al. Nucleic Acids Res. 17, 449 (1989), Green et al. Virology 161, 153-159 (1987), and Richardson et al. J. Virol. 51, 860-862 (1984). the disclosure of these references is incorporated herein by reference.

10 In a seventh aspect the present invention consists in a ligand for antigen-specific T lymphocytes, the ligand comprising a multimeric peptide-MHC complex in which the peptide is selected from the group consisting of ANMDISTGHMILAYME, WQALCAYQAEPNTCAT,  
15 PYDHARIKLKVESSPS, LSHTIADFWQMWWESG, DFWQMWWESGCTVIVM, WESGCTVIVMLTPLVE, VIVMLTPLVEDGVKQC, SEHIWCEDFLVRSFYL, WCEDFLVRSFYLKNVQ, EDFLVRSFYLKNVQTQ, DFRRKVNKCGRSCP, YILIDMVLNRMAKGVK, FEFALTAVAEVNAIL, SNMDISTGHMILSYME, WEALCAYQAEPNSSFV, TYDHSRVLLKAENSHS, LPATVADFWQMWWESG,  
20 DFWQMWWESGCVVIVM, WESGCVVIVMLTPLAE, VIVMLTPLAENGVRQC, SEHIWCEDFLVRSFYL, WCEDFLVRSFYLKNLQ, EDFLVRSFYLKNLQTN, DFRRKVNKCGRSCP, YVLIDMVLNMAKGA, FEFALTAVAEVNAIL and conservative substitutions therein.

In a preferred embodiment the peptide is VIVMLTPLVEDGVKQC or  
25 VIVMLTPLVED.

In a preferred embodiment of this aspect of the invention the multimer is a dimer or tetramer.

In a further preferred embodiment the ligand is provided with a detectable label.

30 The detectable label may be any one of a number of any such labels well known in the art such as biotin, a fluorophor, or radioisotope.

Further information regarding such ligand can be found in Altman et al., Science 274; 94-96, 1996 and Dunbar et al., Curr. Biol. 8 413-416, 1998. The disclosure of these references is incorporated herein by reference.

35 The ligand of this aspect of the present invention can be used in assessing the risk of an individual of developing type 1 diabetes. The

method would involve measuring the numbers of antigen-specific T lymphocytes in a sample from the individual. Where the ligand is provided with a label this could be done by flow cytometry. Further, as would be readily appreciated the ligand of the present invention could be used *in vivo* for imaging.

Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

The disclosure of all references referred to throughout this specification are incorporated herein by reference.

#### DETAILED DESCRIPTION

In order that the nature of the present invention may be more readily understood preferred forms thereof will now be described with reference to the following examples and Figures.

##### Figure legend

**Fig 1:** Summary of identified T-cell epitope peptides in tyrosine phosphatase IA-2. Bolded boxes contain sequences common to overlapping epitope peptides; unbolded boxes contain epitope peptides presented by both DR3-DQ2 and DR4-DQ8 haplotypes; stippled boxes contain epitope peptides presented only by the DR4-DQ8 haplotype.

**Fig 2:** Proliferative T cell response to IA-2 peptides in subjects at risk for type 1 diabetes; DR4DQ8 homozygous subjects (2a); DR3DQ2 homozygous subjects (2c); heterozygous subjects (2b).

**Fig 3:** T cell responses to peptides in tyrosine phosphatase IA-2 for each group of subjects.

**Fig 4:** RV Ab and islet Ab responses over 5 years in sibs at-risk for type 1 diabetes. A=sib 1, female, HLA-DR3,4; B=sib 2, male, HLA-DR1,4. Arrows indicate RV infections, dotted lines indicate antibody cut-offs.

## RESEARCH DESIGN AND METHODS

### Subjects for epitope study

Peripheral blood was obtained from six at-risk, islet cell antibody (ICA) positive first-degree relatives of people with type 1 diabetes (4 male, 2 female, mean age  $28.5 \pm 15.0$ , range 10-50) and two healthy control subjects (2 males, ages 30, 48). Subjects were selected for type 1 diabetes-associated HLA haplotypes, ie DR4-DQ8 homozygous (two at-risk relatives, one control), DR3-DQ2 homozygous (two at-risk relatives, one control) and DR4-DQ8/DR3-DQ2 heterozygous (two at-risk relatives). All relatives had antibodies to IA-2. Within 14 months of the study, both DR4-DQ8 homozygous relatives developed clinical type 1 diabetes and the first-phase insulin release in response to intravenous glucose in both DR3-DQ2 homozygous relatives fell to below the first percentile, indicating imminent clinical disease. The study was approved by the Ethics Committee, and conducted with informed consent.

### Subjects for epidemiologic study

360 infants in the Australian BabyDiab Study, with a parent or sibling with type 1 diabetes, had serum assayed every 6 months from birth for IAA, GADAb and IA-2Ab. Infants who developed diabetes ( $n=5$ , 2 male, at mean age  $29.5 \pm 10.4$  months) or had either  $>1$  islet Ab or an Ab detected at  $>1$  timepoint ( $n=19$ , 11 male) (group A) were studied for evidence of RV infections, together with 17 (9 male) unrelated age-, sex- and HLA class II-matched infants from the Study either without detectable islet Ab over the same period ( $n=10$ , 3 male) or with only one Ab transiently ( $n=7$ , 6 male) (group B). Thirteen siblings (8 male) of infants in group A were also studied to assess intra-familial transmission of RV. Acute- and convalescent-phase sera were collected from 10 children (5 male, mean age 11 months, range 6-38 months) hospitalised with serologically-proven RV gastroenteritis. These children had no first-degree relatives with type 1 diabetes. The studies were conducted with approval of human ethics committees.

### Tissue typing

HLA alleles were typed by the standard microlymphocytotoxic method for all recognised HLA class I alleles. HLA-DR and DQ types were

determined by sequence-specific oligotyping, following the International Histocompatibility Workshop protocol.

### Peptides

5 A set of 68 16-mer peptides was synthesised (Chiron Technologies, Melbourne, Australia). Sixty-two peptides overlapping by 10 aa spanned the cytoplasmic domain of human IA-2 (aa 601- 979). Six additional 16-mers (aa 713-728, 779-794, 795-810, 831-846, 845-860, 959-974) covered sequences predicted to bind to DR4(\*0401) (13,14). Peptides were synthesised by Fmoc  
10 chemistry and solid phase synthesis, with free amino and free acid carboxy-termini, using base-labile or acid-labile resins as appropriate. Each peptide was dissolved in 100µl 40% acetonitrile in degassed phosphate buffered saline (PBS) and shaken at 4°C overnight, checked for solubility, sonicated in an immersion sonicator for up to 60 min at room temperature  
15 (RT) if necessary, then diluted to 1 mg/ml in PBS. Each peptide was dispensed into 12 wells of a sterile 96-well round-bottomed tissue culture tray (Linbro) and stored at -80°C.

### HLA-DR4 binding

20 Peptide binding to purified DR4(\*0401) was measured directly by a competition enzyme linked immunosorbant assay, as previously described (15,16).

### T-cell proliferation assays

25 Peripheral blood mononuclear cells (PBMC) were separated from heparinised venous blood by Ficoll-Hypaque density centrifugation, washed twice in RPMI 1640 medium and diluted to  $10^6$  cells/ml in RPMI1640 medium containing 10% autologous serum, 20 mM Hepes and  $10^{-5}$ M 2-mercaptoethanol (complete medium). Two  $\times 10^5$  cells were added in 200  
30 µl of complete medium to each well of freshly-thawed, peptide-containing 96-well trays. Each peptide was tested at 10µg/ml in replicates of 12. The first row of each tray contained six wells without antigen (basal) and six wells with 1.8 Lyons flocculating units (Lfu)/ml of preservative-free tetanus toxoid (Commonwealth Serum Laboratories, Melbourne); the last row of  
35 each tray contained six wells with 0.18 Lfu of tetanus toxoid and six wells without antigen. After incubation for 6 days in 5% CO<sub>2</sub> at 37°C, 37 kBq



<sup>3</sup>H-thymidine (ICN, 2.5 TBq/mmol) was added per well; the cells harvested semi-automatically seven hours later and <sup>3</sup>H-thymidine incorporation measured by liquid scintillation counting. As T-cell responses to peptides approximate a Poisson rather than a normal distribution, proliferation was expressed as the % positive of the 12 replicate wells. Positive wells were defined as having cpm > mean + 2 SD of the 12 basal wells for that plate. A T-cell response to a peptide was defined as positive wells  $\geq 40\%$ ; this threshold was the mean + 2SD of the 136 responses of the controls to all peptides (mean 6%, SD 17%). T-cell epitopes were defined as being within peptides that elicited a response in two at-risk relatives with the same HLA haplotype, eg both DR4-DQ8 homozygotes, or one DR4-DQ8 homozygote and at least one DR3-DQ2/DR4-DQ8 heterozygote. The reproducibility of T-cell proliferation to tetanus (1.8 Lfu/ml) was tested by repeat assays weekly for four weeks in three subjects; intra-assay CVs ranged from 13.1 to 18.9 % and the inter-assay CV from 14.2 to 26.2%.

### Antibody (Ab) assays

#### IAA

IAA were assayed by fluid-phase <sup>125</sup>I-insulin precipitation (17). Results were expressed as percent of total counts precipitated. The control range (mean + 2 SD) <5.5%, was derived from 190 healthy children (mean age 9.7; range 4.9-15.5 years). The inter-assay coefficient of variation (COV) is 16%.

#### GAD and IA-2Ab

GADAb and IA-2Ab were assayed by precipitation of <sup>35</sup>S-methionine labelled recombinant human proteins and results were expressed as arbitrary units, described elsewhere (6). The control range for GADAb derived by receiver operator curve (ROC) analysis of 246 control subjects and 135 newly-diagnosed patients is <5U, with an inter-assay COV of 21%. In the international GADAb proficiency test #2, the assay scored 100% for sensitivity, specificity, validity and consistency. The control range for IA2Ab, derived by ROC analysis of 145 control subjects and 94 newly-diagnosed patients is <3 U, with an inter-assay COV of 34%.

**Rotavirus IgA (RVA) and IgG (RVG) Ab**

Levels of RVA and RVG were measured initially at a serum dilution of 1:100 by direct enzyme immunoassay (EIA), described previously for RVA in secretions (18,19). Sera were also tested at 1:500 as necessary. Optimal  
5 dilutions of reagents determined by chequerboard titration were dispensed in 100  $\mu$ l aliquots. SA11 RV antigen and MA104 cell control antigen were prepared as previously (18). EIA antigens diluted in 0.06M sodium carbonate-bicarbonate buffer pH 9.6 were adsorbed to microtiter plate wells (NUNC Maxisorp) for 2 h at 37°C. After washing in phosphate-buffered  
10 saline containing 0.05% (v/v) Tween 20 (PBS-T20) and addition of sera diluted in PBS-T20 containing 0.5% (w/v) casein (PBS-T20-C), plates were held overnight at 4°C. Following washing, affinity-purified sheep anti-human IgA or IgG conjugated to horseradish peroxidase (Silenus, Australia) diluted in PBS-T20-C was added for 1.5 h at 37°C. Negative and  
15 positive controls, and colour development with TMB substrate, have been described (18). A standard human serum pool arbitrarily assigned to contain 20,000 units (U) RVG/ml and 30,000 U RVA/ml was titrated in doubling dilutions on each plate to construct a standard curve from which U/ml of RVG and RVA in test sera were determined. The inter-assay COV for both  
20 RVA and RVG was 20%. The positive/negative cut-off (241U) for RVA was determined from the mean+2SD in 25 cord sera. As all cord sera are RVG positive, the cut-off (550U) for RVG was the mean+2SD of the lower level in sera collected from 25 infants at 6 and 12 months of age, to allow for decay of transplacentally-acquired RVG. The specificity of these assays was shown  
25 previously (14,15).

**CoxsackieB IgM Ab (CBVM)**

CBVM were measured by EIA (16) in 82 sera, 47 with significant increases in RVA or RVG, as controls for specificity of association between  
30 RV and islet Ab. In young children the assay detects homotypic responses that become heterotypic (ie recognize multiple serotypes of CBV) with increasing age (20). Sera at 1:400 dilution were first screened against pooled antigens from CBV serotypes 4 and 5; positive sera were retested with individual antigens. The cut-off was the mean+3SD of 10 known negative  
35 serum samples/tray. The optimum serum dilution (1:400) was derived from previous titrations to 1:10,000, and specificity established by demonstrating

no crossreactivity with sera positive for antibodies to Epstein-Barr, measles, mumps and hepatitis A viruses, *Mycoplasma pneumoniae* and rheumatoid factor.

5    **Thyroid peroxidase antibodies (TPOAb)**

TPOAb were measured with the ELI test<sup>R</sup> anti-TPO kit (Henning Berlin GMBH)

**Anti-nuclear antibodies (ANA)**

10       ANA were measured with the HEp 2000<sup>TM</sup> fluorescent ANA-Ro test system (Immunoconcepts, Sacramento).

**Database searches**

15       Similarities to the sequences of epitope peptides or their common overlapping sequences were sought using FASTA 2 software. Databases searched were Genbank (GBTrans) (1997), Swissprot (1997), Protein Research Foundation of Japan (PRFJ) (1997) and Ooi Japan (OOIJ) (1983). No statistical significance was assigned to search results because the databases included many sequences homologous to IA-2, eg B220, CD45, IA-2  $\beta$ ,  
20   phogrin, IAR, and other tyrosine phosphatases. Infectious or dietary agents were selected on the basis of potential biological relevance, as in other studies (21), from the first 60 best matches in the PRFJ and OOIJ databases and from the first 100 in the larger GBTrans and Swissprot databases.

25    **Statistical analysis**

Any change  $\geq 2$  inter-assay COV between consecutive samples was considered to be significant, a standard practice for virological assays (18). Thus, a rise  $\geq 32\%$  for IAA,  $\geq 42\%$  for GADAb and  $\geq 68\%$  for IA-2Ab was considered significant; for RVA or RVG a rise of  $\geq 40\%$ , and for CBVM any  
30   increase above the cut-off, was considered indicative of infection during the preceding 6-month period. Either RVA or RVG was taken to indicate RV infection, as at-risk infants may have impaired IgA responses (22), and RVG does not rise immediately when pre-existing RVG is high (23,24).

A significant increase in any Ab was scored as 1, otherwise 0.  
35   Concordance (11 or 00) and discordance (10 or 01) for any islet Ab with any RV Ab was used for  $\chi^2$  analysis with Yates' correction to determine the

association over all samples in groups A and B. For greater statistical stringency, we employed a permutation analysis (25) in which the odds ratio (OR) was calculated as  $(11 \times 00)/(10 \times 01)$  for the association in each infant. The result was converted to  $\log_{10}$ , and the mean log OR of all 24 unrelated group A infants calculated. The distribution of the mean log OR expected if there was no association (null hypothesis) was derived by 1000 permutations of the positions of the scores of 1 and 0 for islet and RV Ab in each child, calculating the mean log OR at each permutation. The experimental mean log OR was then compared to the distribution of the mean log ORs from the permutations to determine the probability of association (25).

## RESULTS

From 68 16-mer peptides encompassing cytoplasmic IA-2, 11 peptides (from aa 685, 713, 745, 787, 793, 805, 841, 845, 847, 919 and 959) elicited T-cell responses in relatives homozygous for DR4-DQ8 and two peptides (from aa 799 and 889) elicited responses in one DR4-DQ8 homozygous and one DR4-DQ8/DR3-DQ2 heterozygous relative (Figure 1, Figure 2). All these epitope peptides bound to HLA-DR4 (26) (Table 1). Five peptides (from aa 799, 805, 841, 847, 919) elicited responses in the DR3-DQ2 homozygous relatives, and the first four of these also in the matched control. Notably, peptide EDFLVRSFYLKENVQTQ (aa 847-862) elicited responses in both DR3-DQ2 and DR4-DQ8 homozygous controls, as well as in one DR3-DQ2 homozygous, one heterozygous and both DR4-DQ8 homozygous at-risk relatives. Peptide VIVMLTPLVEDGVKQC (aa 805-820) elicited a response in all at-risk relatives and in the DR3-DQ2 homozygous control; in each case it was the highest response (relatives,  $86 \pm 20\%$  positive wells; control 100% positive wells). Alignment of the IA-2 epitope peptides with related sequences in human tyrosine kinase IAR (5) revealed identities of  $86 \pm 12\%$  and similarities of  $92 \pm 10\%$  (mean  $\pm$  SD) (Table 2).

Epitope peptides of IA-2 shared identity/similarity with several environmental agents (Table 1). The dominant epitope peptide VIVMLTPLVEDGVKQC had sequence identities of 75-45% and similarities of 100-64% over 8-11 aa to sequences within the VP7 protein of rotavirus (serotype G3, strain P) and lesser identity to the G1 and G2 subtypes (Table 3). VIVMLTPLVEDGVKQC also has sequence identities with the capsid protein C of Dengue flavivirus, the major capsid protein of human

cytomegalovirus, the haemagglutinin proteins of canine distemper virus (known to infect humans) and the closely-related measles virus, and the E2 protein of hepatitis C virus. It also had 50% identity and 71% similarity over 14 aa with the HI 1338 protein of the bacterium *Haemophilus influenzae*.

- 5 Most of the sequence similarities were in the region of overlap, VIVMLTPLVE (aa 805-814), with the preceding epitope peptide (aa 799-814). The rotavirus VP7 protein also had 75% identity and 92% similarity over 12 aa (aa 18-29) (or 75% and 100% over 9 aa) to GAD65 (aa 117-128), and GAD67 (aa 123-134) (Tables 4 & 5).

- 10 Peptide aa 685-700 had 56-71% identity and 78-86% similarity to the BTRF1 and BRRF2 proteins of Epstein-Barr virus, and 50% identity and 100% similarity over 10 aa to the genome polyprotein of rhinovirus 14, the common cold virus (Table 1).

- 15 Peptide aa 787-802 had 58% identity and 75% similarity over 12 aa to the M polyprotein precursor of hantavirus, and 71% identity and similarity over 7 aa to sequences within the genome polyprotein of other members of the flavivirus family, ie Japanese encephalitis, Kunjin, West Nile and Murray Valley encephalitis viruses. Most of the sequence similarities were in the region of overlap DFWQMVWESG (aa 793-802) with the succeeding epitope peptide (aa 793-808).

- 20 Peptide aa 841-856 had 64% identity and 82% similarity over 11 aa to NADH ubiquinone reductase proteins in wheat and broad beans, and epitope peptide aa 919-934 had 60% identity and 80% similarity over 10 aa to kappa casein in cow's milk. Most of the sequence similarities were in the region of overlap, EDFLVRSFYI (aa 847-856), with the two succeeding epitope peptides (aa 845-860, 847-856).

- 25 Peptide aa 919-934 had 63% identity and 88% similarity over 8 aa to the surface glycoprotein of Herpes simplex virus. Peptide aa 959-974 had 67% identity and 78% similarity over 9 aa to the major capsid protein of cytomegalovirus (HHV5) and Herpes saimiri virus (which can infect human lymphocytes), and 50% identity and 70% similarity over 10 aa to replication protein E1 of papilloma virus strains 28 and 18. It also had 45% similarity and 73% similarity over 11 aa to the E2L polyprotein of vaccinia and variola (HHV6) viruses. No sequence similarities were detected with the remaining
- 35 three epitope peptides, aa 713-728, 745-760, 889-904.

In the epidemiologic study the first appearance or an increase in islet Ab (Table 6) was significantly associated by standard  $\chi^2$  test with an increase in RVA or RVG during the same 6-month period ( $\chi^2_{YC}$  13.2,  $p < 0.0003$  group A,  $\chi^2_{YC}$  7.7,  $p < 0.005$  group B). As  $\chi^2$  may be biased by high numbers of events the more stringent permutation analysis was then applied. The mean concordance of islet and RV Ab in serial samples from the 24 group A infants analysed by the log OR was 1.024. The mean log OR from 1000 permutations of 1 (significant increase) and 0 (no increase) scores per infant were normally distributed between -0.8 and 1.0 (Fig 3). The observed association was therefore confirmed as highly significant ( $p < 0.001$ ).

IAA, GADAb and IA-2Ab appeared at  $10 \pm 21$  (mean  $\pm$  sd),  $22 \pm 17$  and  $19 \pm 14$  months respectively. Not all islet Ab appeared in all infants, but IAA first appeared with an increase in RV Ab in 13/21 (62%), GADAb in 10/20 (50%) and IA-2Ab 12/14 (86%) (eg Fig 4).

There was no association of CBVM with increases in islet Ab. Of 82 sera tested for both RV and CBVM, 35 had increases in islet Ab but only two of these, with GADAb, were also positive for CBVM (one of each serotype 4 and 5). In the 47 RV Ab positive sera, CBVM were detected to serotype 4 in four and to serotype 3 in one; in the RV negative sera, CBVM were detected to serotype 4 in one and serotype 5 in two.

As evidence for the specificity of the islet Ab response, TPO Ab measured in 27 concordant islet/RV Ab events were increased only once (from a raised level of 190 to 560 units), and were not increased in the non-concordant events; furthermore, ANA were not detected in concordant islet/RV Ab events.

There was no apparent cross-reactivity between islet antigens and RV at the Ab level. Thus, when four sera containing GADAb, IA-2Ab and RV Ab were adsorbed on high titre RV overnight and then retested, RVA and RVG decreased a mean of 57% and 40% respectively, whereas GADAb (7%) and IA-2Ab (0%) were unchanged.

In the group A infants, IAA, GADAb and IA-2Ab appeared or increased with repeated RV infections (Table 6). In the group B infants, transient Ab were IA-2Ab and IAA in 6/7 and 1/7 cases respectively. When RV Ab were compared in 52 concurrent samples from 13 paired at-risk siblings, infection occurred in both sibs 18 times, in neither 17 times, and in only one 17 times

( $\chi^2_{YC}$  6.4,  $p < 0.02$ ) over the same 6 month period, ie 51% had concurrent infection.

The type 1 diabetes HLA-DR4 susceptibility haplotype was present in all infants ( $n=17$ ) in whom any islet Ab increased above the cutoff only with RV infection and in all infants ( $n=10$ ) in whom any islet Ab increased without RV infection. However, the HLA-DR3 susceptibility haplotype was present in only 4/17 (24%) of the former concordant compared to 7/10 (70%) of the latter discordant infants ( $p < 0.05$ ). HLA-DQ2-linked DR alleles (DR3 and DR7) were present in 6/17 (35%) concordant compared to 9/10 (90%) of discordant infants ( $p < 0.02$ ).

In the 10 unrelated children hospitalised with proven RV infection, GADAb were detected in one acute and another convalescent serum and IA2Ab in one acute and three convalescent sera (Table 7).

## DISCUSSION

Thirteen peptides within the intracytoplasmic domain of IA-2, all of which could be presented by HLA-DR4 encoded by the DR4-DQ8 haplotype, elicited T-cell responses in at-risk relatives. The overlap of these peptides suggests nine epitopes. Five peptides, between aa 799-934, elicited responses in relatives bearing either the DR4-DQ8 or DR3-DQ2 susceptibility HLA haplotypes. The remaining peptides elicited responses only in relatives bearing the DR4-DQ8 haplotype. At least two sources of these epitopes are indicated by the very high degree of homology between the two tyrosine phosphatases, IA-2 and IAR.

Interestingly, four peptides elicited responses in the DR3-DQ2 homozygous control, and one of these four also in the DR4-DQ8 homozygous control. Other evidence demonstrates that T cells in normal individuals are capable of reacting to autoantigens (11,27-29). The important inference, however, is that these four epitope peptides (shared sequences VIVMLTPLVE, EDFLVRSFYI) should contain the strongest clues to crossreactive epitopes, eg in environmental agents that could trigger or exacerbate islet autoimmunity.

The contribution of environment to type 1 diabetes can be gauged from the lack of concordance for disease in the majority of identical twins (30). However, the environmental factors responsible remain enigmatic. Some viruses such as Coxsackievirus (31) and rubella (32), as well as the

rodenticide "Vacor" (33), directly damage pancreatic islet  $\beta$ -cells and are associated with  $\beta$ -cell autoimmunity, but such examples are rare, and evidence for persisting infection of  $\beta$ -cells is lacking (34). Infectious agents could also trigger  $\beta$ -cell autoimmunity indirectly (reviewed in 35), particularly by activating T cells crossreactive with islet proteins, a mechanism termed molecular mimicry.

Molecular mimicry has been proposed between the islet autoantigen glutamic acid decarboxylase 65 (GAD65) (amino acids, aa 257-273) and the P2C protein of Coxsackievirus B4, which share 59% identity and 76% similarity over 17 aa (36). This peptide from GAD65 elicits T-cell responses in humans with type 1 diabetes (29) and in the non-obese diabetic (NOD) mouse model (37). T-cell responses to Coxsackie virus B (strain unstated) have been reported in recently-diagnosed type 1 diabetes (21). However, evidence for mimicry is weak, as two overlapping GAD peptides that share the sequence don't elicit T-cell responses in the same individuals with diabetes (36), stronger responses occur in healthy controls (29), and other studies (38,39,40) have not found responses to the CBV-like sequence in GAD. On the other hand, increased IgM to CBV3 and 5 has been found in the sera of pregnant mothers whose infants subsequently developed diabetes (41,42), and CBV3, 4 and 5 infections have been associated with islet cell Ab in children and adolescents with first-degree relatives with diabetes (43).

Evidence for a role of viral infection close to diagnosis of type 1 diabetes is the finding that IgM responses to Coxsackievirus (44) and T-cell responses to both Coxsackievirus and adenovirus, but not to the Herpes viruses, or to mumps, polio, tick-borne encephalitis virus or rotavirus (21), were higher in people at diagnosis than in controls. The dominant IA-2 epitope peptide aa 805-820 has high identity and similarity over 8-11 aa to sequences within several viruses. The nonamer in this peptide predicted to bind to DR4 (14) is VIVMLTPLV. The most likely anchor residues for binding (Table 1; 10,11) are unbolded; the bolded residues are therefore most likely to be T-cell receptor contact residues (TCR-CR) potentially critical for molecular mimicry. The strongest similarity is with the VP7 protein of human rotavirus particularly (serotype 3, strain P, reovirus family, Table 2). VP7 contains the sequence IIVILSPLL (aa 41-49) with identical TCR-CR; although the anchor residues differ they are equally effective for DR4 binding (14). By using HLA-DQ8(\*0302) binding peptides curated in the



MHCPEP Database (45) to derive a matrix for DQ8, two overlapping decamers in the same IA-2 region were also predicted to bind to DQ8 (Table 1), consistent with the high T-cell responses seen to this epitope. The first DQ8 frame, IIVILSPLLN, has 100% similarity to VP7 in its potential TCR-CR. VP7 is one of the two immunogenic proteins that confer serotype specificity and is currently being used by others to develop a rotavirus vaccine (46).

Jones and Crosby (21) noted a sequence similarity between GAD 65 (aa 108-137) and rotaviral VP7 protein, although they could not elicit increased T-cell responses to whole rotavirus (strain unstated) in people with recently-diagnosed type 1 diabetes. The cited GAD65 sequence contains a T-cell epitope peptide MNILLQYVVKSFDNST (aa 115-130, with 88% homology to GAD67, aa 121-136), in mice transgenic for human HLA-DR4 (47). We have identified this epitope (aa 115-129) in at-risk relatives and healthy controls homozygous for DR4-DQ8. The predicted DR4-binding nonamer within the GAD65 peptide is ILLQYVVKS, and for VP7 is ILLNYVLKS; in GAD 67 the equivalent region is ILLNYVRKT. GAD65 therefore has 100% similarity and identity with VP7 in the potential TCR-CR (Table 4). The region of VP7 containing both sequence similarities is immunologically interesting. It contains many hydrophobic potential anchor residues for HLA class II molecules, and an epitope for cytotoxic T cells in C57/Bl6 mice immunized with rotavirus (48,49), adjacent to the sequences with similarity to GAD65 and IA-2. The GAD and IA-2 similarities raise the interesting possibility that rotavirus infection could simultaneously activate T cells to two type 1 diabetes autoantigens (see also below).

Rotavirus is a major enteric pathogen of early childhood (50) that causes regular winter outbreaks of gastroenteritis in daycare centres. Children can have multiple infections by different serotypes. Early-age daycare was found to confer increased risk for type 1 diabetes (51), consistent with a link between rotavirus and type 1 diabetes. Furthermore, the most marked increase in type 1 diabetes incidence over the last decade (11%/yr) has occurred in the 0-4 year old age group(62).

VP7, the major outer capsid protein of RV, is an important determinant of virulence and induces virus-neutralizing antibodies (50). However, the elimination of RV following infection is predominantly due to T cells (52).

Proliferative CD4 T-cell responses have been detected in humans within 4-6 weeks following rotavirus re-infection (53). These CD4 T cells were of the CD45RA negative (memory),  $\alpha 4\beta 7$  integrin-high subset, indicating that gastrointestinal immune responses generate  $\alpha 4\beta 7$  positive T-cell memory. An interesting convergence is that GAD-responsive T cells from people with recently-diagnosed type 1 diabetes are  $\alpha 4\beta 7$  positive (84) and T cells in the early phase of insulinitis in NOD mice are  $\beta 7$ -integrin high (55). These data suggest that rotavirus-responsive CD4,  $\alpha 4\beta 7$  positive T cells could migrate selectively to the islets. As the T-cell contact residues in the similar RV VP7 and IA-2 sequences appear to be identical (56), there is potential for molecular mimicry. All human RV serotypes in the Genbank database contain the GAD-related sequence (Table 4). These IA-2- and GAD-like sequences in VP7 span an epitope (aa 31-40) for cytotoxic T cells in C57/Bl6 mice immunized with RV (48,49), consistent with this region being strongly immunogenic. RV infection could therefore simultaneously activate T cells crossreactive to two islet autoantigens in genetically-susceptible infants.

In addition to molecular mimicry, RV may directly infect islets. This possibility is supported by reports of pancreatitis following rotavirus infection (57,58), and by the fact that rotavirus is related to reovirus, which can infect human (59) and mouse (60) islets.

The similarities of the other viruses with peptide VIVMLTPLVEDGKQC and with the other IA-2 epitope peptides include anchor residues for DR4(\*0401), but the potential TCR-CR are not quite as remarkable as for rotavirus.

IA-2 epitope peptide aa 919-934, as well as being similar to the surface glycoprotein of Herpes simplex virus, has 60% identity and 80% similarity over 10 aa, that include the predicted DR4 binding nonamer ILIDMVLNR, with bovine kappa casein YIPIQYVLSR (aa 26-35), although the similarity of the potential TCR-CR is only 40%. T-cell responses to whole casein have been reported in type 1 diabetes (61) but the role of bovine milk proteins as potential aetiological agents in type 1 diabetes is controversial (62). There is also a high similarity of the common sequence EDFLVRSFYI (aa 847-856) of the IA-2 epitope peptides encompassing aa 841-898 with sequences in wheat and broad bean proteins. Peptide aa 841-856 contains a DR4 binding motif WCEDFLVRS (cf VLNDFLVRS in wheat and beans) and a predicted DQ8

binding motif **IWCEDFLVRS** (cf **RVLNDFLVRS** in wheat and beans).  
Antibodies to NADH reductase occur in some people with recently  
diagnosed diabetes. The class II MHC molecule of NOD mice, **I-A8<sup>7</sup>**, is the  
structural counterpart of human **DQ8(\*0302)**, and NOD mice fed casein  
5 supplement (Harrison LC, unpublished), wheat flour and to a lesser extent  
soya bean meal (63), have an accelerated onset of diabetes.

In conclusion, the present inventors have identified T-cell epitope  
peptides in the intracytoplasmic domain of the type 1 diabetes autoantigen,  
tyrosine phosphatase **IA-2**, whose sequence analysis suggests that immunity  
10 to rotavirus (whose **VP7** sequence mimics epitopes in both **IA-2** and **GAD**)  
and possibly other viruses and dietary proteins, could predispose to type 1  
diabetes by activating crossreactive T cells.

Our epidemiologic findings suggest that RV infection may trigger or  
exacerbate islet autoimmunity, on the **HLA-DR4** background. As rotavirus  
15 vaccines currently undergoing trials are live viruses containing the **VP7**  
leader sequence, our findings have implications for development of safe  
rotavirus vaccines to protect against islet autoimmunity and prevent the  
development of type 1 diabetes.

It will be appreciated by persons skilled in the art that numerous  
20 variations and/or modifications may be made to the invention as shown in  
the specific embodiments without departing from the spirit or scope of the  
invention as broadly described. The present embodiments are, therefore, to  
be considered in all respects as illustrative and not restrictive.

### Environmental agent

potential anchor residues for binding to DR4 and DR8 are denoted by x

• HIV = human herpes virus;

TABLE 2: Epitopic peptides in IA-2 and homologous regions in IAR

Peptide #	T cell response					Position of sequence	Peptide sequence	Identity (%)	Homology (%)
	DR3,3;DQ2,2 control n=1	DR4,4;DQ8,8 control n=1	DR3,3;DQ2,2 relatives n=2	DR3,4;DQ2,8 relatives n=2	DR4,4;DQ8,8 relatives n=2				
15			1	2		IA-2 aa685-700 IAR aa721-736	A N M D I S T G H M I L A Y M E S N M D I S T G H M I L S Y M E	88	88
20				2		IA-2 aa713-728 IAR aa749-764	W Q A L C A Y Q A E P N T C A T W E A L C A Y Q A E P N S S F V	69	75
26				2		IA-2 aa745-760 IAR aa781-796	P Y D H A R I K L K V E S S P S T Y D H S R V L L K A E N S H S	56	69
34				2		IA-2 aa787-802 IAR aa823-838	L S H T I A D F W Q M V W E S G L P A T I A D F W Q M V W E S G	81	88
35			1	2		IA-2 aa793-808 IAR aa829-844	D F W Q M V W E S G C T V I V M D F W Q M V W E S G C V V I V M	94	94
37	1		1	1	1	IA-2 aa799-814 IAR aa835-850	W E S G C T V I V M L T P L V E W E S G C V V I V M L T P L A E	88	94
38	1		2	2	2	IA-2 aa805-820 IAR aa841-856	V I V M L T P L V E D G V K Q C V I V M L T P L A E N G V R Q C	81	94
45	1		1	1	2	IA-2 aa841-856 IAR aa877-892	S E H I W C E D F L V R S F Y L S E H I W C E D F L V R S F Y L	100	100
46				2		IA-2 aa845-860 IAR aa881-896	W C E D F L V R S F Y L K N V Q W C E D F L V R S F Y L K N I Q	94	100
47	1	1	1	1	2	IA-2 aa847-862 IAR aa883-898	E D F L V R S F Y L K N V Q T Q E D F L V R S F Y L K N I Q T N	88	100
54				1	1	IA-2 aa889-904 IAR aa925-940	D F R R K V N K C Y R G R S C P D F R R K V N K C Y R G R S C P	100	100
59			1	1	2	IA-2 aa919-934 IAR aa955-970	Y I L I D M V L N R M A K G V K Y V L I D M V L N K M A K G A K	81	100
66				2		IA-2 aa959-974 IAR aa995-1010	F E F A L T A V A E E V N A I L F E F A L T A V A E E V N A I L	100	100

TABLE 3

## IA-2-RV similarities

IA-2 Native seq a	805	806	807	808	809	810	811	812	813	814
Peptide aa #	1	2	3	4	5	6	7	8	9	10
PREDICTED TCR-CR FROM DR4										
IA-2	I	V	L	L	S	P	L	S	N	E
VP7 of G3 RV strain P	I	V	L	L	S	P	L	S	N	N
Predicted anchor to DR4(*0401)										
VP7 Native seq a	40	41	42	43	44	45	46	47	48	49
VP7 of G3 RV: RV-3 & 3 rel strains	I	V	L	L	S	P	L	S	N	N
VP7 of G3 RV: S12/85 & 2 rel strains	S	V	A	L	F	A	L	T	K	R
VP7 of G1 RVs (9 strains)	T	V	A	L	F	A	L	T	R	R
VP7 of G1 RVs (6 strains)	T	V	A	L	F	A	L	T	R	R
VP7 of G1 RVs (1 strain)	T	V	T	L	F	A	L	T	R	R
VP7 of G1 RVs (1 strain)	S	V	A	L	F	A	L	T	R	K
VP7 of G1 RVs (1 strain)	S	V	A	L	F	A	L	T	R	R
VP7 of G1 RVs (1 strain)	S	V	A	L	F	A	L	T	R	R
VP7 of G1 RVs (1 strain)	S	V	A	L	F	A	L	T	R	R
VP7 of G1 RVs (1 strain)	S	V	A	L	F	A	L	T	R	R
VP7 of G2 RVs (4 strains)	S	V	A	L	F	A	L	T	R	R
PREDICTED TCR-CR FROM DR4										
IA-2	I	V	L	L	S	P	L	S	N	E
VP7 of G3 RV strain P	I	V	L	L	S	P	L	S	N	N
VP7 of G3 RV: RV-3 & 3 rel strains	S	V	A	L	F	A	L	T	K	R
VP7 of G3 RV: S12/85 & 2 rel strains	T	V	A	L	F	A	L	T	R	R
VP7 of G1 RVs (9 strains)	T	V	A	L	F	A	L	T	R	R
VP7 of G1 RVs (6 strains)	T	V	A	L	F	A	L	T	R	R
VP7 of G1 RVs (1 strain)	T	V	T	L	F	A	L	T	R	R
VP7 of G1 RVs (1 strain)	S	V	A	L	F	A	L	T	R	K
VP7 of G1 RVs (1 strain)	S	V	A	L	F	A	L	T	R	R
VP7 of G1 RVs (1 strain)	S	V	A	L	F	A	L	T	R	R
VP7 of G1 RVs (1 strain)	S	V	A	L	F	A	L	T	R	R
VP7 of G2 RVs (4 strains)	S	V	A	L	F	A	L	T	R	R
BINDING TO DR4: V GOOD P1, P4, 8, EXCELL P7, V GOOD P9										
TCR-CR: EXCEL P2,3,5,8, POOR P10										
BINDING TO DR4: V GOOD P1, POOR P4, 6,7,9										
TCR-CR V GOOD										
BINDING TO DR4: V GOOD P1, P4, 6,7, POOR P9										
TCR-CR: P2 EXCELLENT, P3,5,8 OK, P10 POOR										
IA-2	I	V	L	L	S	P	L	S	N	E
VP7 of G3 RV: P strain	I	V	L	L	S	P	L	S	N	N
Predicted anchor to DQ8										
VP7 Native seq a	40	41	42	43	44	45	46	47	48	49
VP7 of G3 RV: RV-3 & 3 rel strains	I	V	L	L	S	P	L	S	N	A
VP7 of G3 RV: S12/85 & 2 rel strains	S	V	A	L	F	A	L	T	K	A
VP7 of G1 RVs (9 strains)	T	V	A	L	F	A	L	T	R	A
VP7 of G1 RVs (6 strains)	T	V	A	L	F	A	L	T	R	A
VP7 of G1 RVs (1 strain)	T	V	T	L	F	A	L	T	R	A
VP7 of G1 RVs (1 strain)	S	V	A	L	F	A	L	T	R	A
VP7 of G1 RVs (1 strain)	S	V	A	L	F	A	L	T	R	A
VP7 of G1 RVs (1 strain)	S	V	A	L	F	A	L	T	R	A
VP7 of G1 RVs (1 strain)	S	V	A	L	F	A	L	T	R	A
VP7 of G1 RVs (1 strain)	S	V	A	L	F	A	L	T	R	A
VP7 of G2 RVs (4 strains)	S	V	A	L	F	A	L	T	R	A
PREDICTED TCR-CR FROM DQ8										
IA-2	I	V	L	L	S	P	L	S	N	E
VP7 of G3 RV strain P	I	V	L	L	S	P	L	S	N	N
VP7 of G3 RV: RV-3 & 3 rel strains	S	V	A	L	F	A	L	T	K	A
VP7 of G3 RV: S12/85 & 2 rel strains	T	V	A	L	F	A	L	T	R	A
VP7 of G1 RVs (9 strains)	T	V	A	L	F	A	L	T	R	A
VP7 of G1 RVs (6 strains)	T	V	A	L	F	A	L	T	R	A
VP7 of G1 RVs (1 strain)	T	V	T	L	F	A	L	T	R	A
VP7 of G1 RVs (1 strain)	S	V	A	L	F	A	L	T	R	A
VP7 of G1 RVs (1 strain)	S	V	A	L	F	A	L	T	R	A
VP7 of G1 RVs (1 strain)	S	V	A	L	F	A	L	T	R	A
VP7 of G1 RVs (1 strain)	S	V	A	L	F	A	L	T	R	A
VP7 of G1 RVs (1 strain)	S	V	A	L	F	A	L	T	R	A
VP7 of G2 RVs (4 strains)	S	V	A	L	F	A	L	T	R	A
BINDING TO DQ8: EXCEL P1, P4, GOOD-POOR P8, POOR P10										
TCR-CR: EXCEL P2,8, 7, V GOOD P3,5, POOR P9										
BINDING TO DQ8: POOR P1, EXCEL P4, V GOOD P8, POOR P10										
TCR-CR: EXCEL P2,7, OK P3, POOR P5,9										
BINDING TO DQ8: EXCEL P1,8, V GOOD P4, POOR P10										
TCR-CR: GOOD P2, V GOOD P3,5,7, EXCEL P8, POOR P9										

TABLE 4: sequence similarities between IA-2, rotavirus and GAD 65 and 67

Protein	Sequence †															
DR4																
DQ8																
IA-2 aa801-816																
Rotavirus VP7 aa16-49																
GAD65 aa115-129																
GAD67 aa121-135																

† potential anchor residues for binding to DR4 and DQ8 are denoted by x.

TABLE 5

## GAD-RV similarities

GAD85 Native	117	118	119	120	121	122	123	124	125	126
Peptide aa #	1	2	3	4	5	6	7	8	9	10
PREDICTED TCR CONTACT RESIDUES (TCR-CR) FROM DR4										
GAD65	I	L	L	D	Y	V	V	K	S	F
GAD67	I	L	L	N	Y	V	R	K	S	F
VP7 of G3 RV strains P, S12/85, 7 others	I	L	L	N	Y	V		K	S	
Predicted anchor to DR4(*0401)										

VP7 Native sr	17	18	19	20	21	22	23	24	25	26
All RV strains										
VP7 of G1 RVs (20 strains)	I	L	L	N	Y			K	S	V
VP7 of G2 RVs (4 strains)	I	L	L	N	Y			K	S	
VP7 of G3 RV strains P, S12/85, 7 others	I	L	L	N	Y	V		K	S	
VP7 of G3 RVs: RV-3 and 5 related strains	I	L	L	N	Y	V		K	S	
NB: RV-3 being trialled as a vaccine										

## PREDICTED TCR-CR FROM DR4

GAD65	L	L		Y		K	F
GAD67	L	L		Y		K	F
VP7 of G3 RV strains P, S12/85, 7 others	L	L		Y		K	
VP7 of G3 RVs: RV-3 and 5 related strains	L	L		Y		K	
VP7 of G1 RVs (20 strains)	L	L		Y		K	
VP7 of G2 RVs (4 strains)	L	L		Y		K	
BINDING TO DR4: EXCEL P1,4,8,9, GOOD P7;							
TCR-CR ALL RV EXC P2,3,5,8, GOOD P10							
BINDING TO DR4: EXCEL P1,4,9, GOOD P6,7							
BINDING TO DR4: EXCEL P1,4,8,9, GOOD P7							

## PREDICTED TCR-CR FROM DQ8

GAD65	I	L	L	D	Y	V	V	K	S	F
GAD67	I	L	L	N	Y	V	R	K	S	F
VP7 of G3 RV strains P, S12/85, 7 others	I	L	L	N	Y	V		K	S	
Predicted anchor to DQ8										
VP7 Native sr	17	18	19	20	21	22	23	24	25	26

## PREDICTED TCR-CR FROM DQ8

GAD65	L	L		Y	V	V	S
GAD67	L	L		Y	V	R	S
VP7 of G3 RV strains P, S12/85, 7 others	L	L		Y	V		S
VP7 of G3 RVs: RV-3 and 5 related strains	L	L		Y	V		S
VP7 of G1 RVs (20 strains)	L	L		Y	V		S
VP7 of G2 RVs (4 strains)	L	L		Y	V		S
BINDING TO DQ8: EXCEL P1,4, 8,GOOD P10;							
TCR-CR ALL RV EXC P2,3,5,9, GOOD P6,7							
BINDING TO DQ8: EXCEL P1,4, 8,GOOD P10;							
BINDING TO DQ8: EXCEL P1,4, 8,GOOD P10;							





TABLE 7. ISLET AND ROTAVIRUS ANTIBODIES IN ACUTE AND CONVALESCENT  
SERA COLLECTED AFTER ROTAVIRUS INFECTION\*

INFANT		ACUTE	CONVALESCENT	INFANT		ACUTE	CONVALESCENT
1	IAA	nt	0.5	6	IAA	0.4	0.7
	GAD	1.6	0.2		GAD	0.1	0.1
	IA-2	0.7	0.8		IA-2	0.1	0.1
	RVA	6369	3724		RVA	0.1	24180
	RVG	72656	65383		RVG	2248	8411
2	IAA	0.4	0.7	7	IAA	1.1	1.1
	GAD	0.2	0.1		GAD	0.1	0.1
	IA-2	0.2	0.1		IA-2	0.1	0.1
	RVA	98900	10000		RVA	4407	nt
	RVG	4170000	>100000		RVG	5189	1567
3	IAA	0.4	1.1	8	IAA	0.3	1
	GAD	0.1	0.1		GAD	0.1	14
	IA-2	0.1	0.3		IA-2	0.1	9.7
	RVA	0.1	1026		RVA	7584	10001
	RVG	2462	39140		RVG	34560	>100000
4	IAA	nt	nt	9	IAA	0.3	0.6
	GAD	0.5	2.8		GAD	0.2	2.1
	IA-2	1.5	2.8		IA-2	0.1	7.2
	RVA	9673	55700		RVA	6337	4950
	RVG	33046	6390000		RVG	38500	86493
5	IAA	0.4	0.3	10	IAA	0.5	1.2
	GAD	7.4	4.9		GAD	0.1	0.1
	IA-2	29	5.4		IA-2	0.1	0.1
	RVA	2530	72200		RVA	3125	2888
	RVG	20980	>100000		RVG	50290	67083

\*Convalescent sera were collected 4-8 weeks after gastroenteritis.

Significant levels of islet antibodies are bolded.

## REFERENCES

1. Janeway CA, Travers P, Hunt S, Walport M (1997) Immunobiology. The Immune System in Health and Disease. Current Biology Ltd/Garland Publishing.
2. Rabin DU, Pleasic SM, Shapiro JA, *et al.* (1994) Islet cell antigen 512 is a diabetes-specific islet autoantigen related to tyrosine phosphatases. *J Immunol* 152: 3183-3188.
3. Lan MS, Lu J, Goto Y, Notkins AL. (1994) Molecular cloning and identification of a receptor-type protein tyrosine phosphatase, IA-2, from human insulinoma. *DNA and Cell Biol* 13: 505-514.
4. Solimena M, Dirkx R, Hermel JM *et al.* (1996) ICA512, an autoantigen of type I diabetes, is an intrinsic membrane protein of neurosecretory granules. *EMBO J* 15: 2102-2114.
5. Bonifacio E, Lampasona V, Genovese S, Ferrari M, Bosi E. (1995) Identification of protein tyrosine phosphatase-like IA2 (islet cell antigen 512) as the insulin-dependent diabetes-related 37/40K autoantigen and a target of islet-cell antibodies. *J Immunol* 155: 5419-5426.
6. Colman PG, McNair P, Margetts H *et al.* (1998) The Melbourne Pre-Diabetes Study: prediction of type 1 diabetes mellitus using antibody and metabolic testing. *Medical Journal of Australia*;169:81-4.
7. Cui L, Wei-Ping Y, deAizpurua HJ, Schmidli RS, Pallen CJ. (1996) Cloning and characterization of islet cell antigen-related protein-tyrosine phosphatase (PTP), a novel receptor-like PTP and autoantigen in insulin-dependent diabetes. *J Biol Chem* 271: 24817-24823.
8. Notkins AL, Lu J, Qing L *et al.* (1996) IA-2 and IA-2 b are major autoantigens in type 1 diabetes and the precursors of the 40 kDa and 37 kDa tryptic fragments. *J Autoimmun* 9: 677-672.
9. Hawkes CJ, Wasmeier C, Christie MR, Hutton JC. (1996) Identification of the 37-kDa antigen in type 1 diabetes as a tyrosine phosphatase-like protein (phogrin) related to IA-2. *Diabetes* 45:1187-1192.
10. Schmidli RS, Colman PG, Cui L *et al.* (1998) Antibodies to the novel protein tyrosine phosphatase IAR predict development of insulin-dependent diabetes mellitus (IDDM) in first-degree relatives at-risk for IDDM. *Autoimmunity* 28:15-23.

11. Durinovic-Bello I, Hummel M, Ziegler AG. (1996) Cellular immune responses to diverse islet cell antigens in type 1 diabetes. *Diabetes* **45**: 795-800.
12. Harrison LC, Dempsey-Collier M, Kramer DR, Takahashi K, (1996)  
5 Aerosol insulin induces regulatory CD8 gamma delta T cells that prevent murine insulin-dependent diabetes, *Journal of Experimental Medicine*. **184**: 2167-74.
13. Hammer J, Bono E, Gallazzi F, Belunis C, Nagy Z, Sinigaglia F. (1994)  
10 Precise prediction of MHC class II-peptide interaction based on peptide side-chain scanning. *J Exp Med* **180**: 2353-2358.
14. Brusic V, Rudy G, Honeyman MC, Hammer J, Harrison LC. (1998)  
Prediction of MHC class II-binding peptides using an evolutionary algorithm and artificial neural network. *Bioinformatics*, **14**:121-130.
15. Sinigaglia F, Romagnoli P, Guttinger M, Takacs B, Pink JRL. (1991)  
15 Selection of T-cell epitopes and vaccine engineering. *Meth Enzymol* **203**: 370-386.
16. Harrison LC, Honeyman MC, Trembleau S *et al.* (1997) A  
peptide-binding motif for I-Ag7, the class II major histocompatibility complex (MHC) molecule of NOD and Biozzi AB/H mice. *J Exp Med* **185**:  
20 1013-1023.
17. Vardi P, Dib S, Tuttleman M *et al.* (1987) Competitive insulin  
autoantibody assay. Prospective evaluation of subjects at high risk for  
development of type 1 diabetes mellitus. *Diabetes* **36**:1286-91.
18. Coulson BS, Grimwood K, Bishop RF, Barnes GL. (1989) Evaluation of  
25 end-point titration, single dilution and capture enzyme immunoassays for measurement of antirotaviral IgA and IgM in infantile secretions and serum. *Journal of Virological Methods*. **26**:53-65.
19. Coulson BS, Grimwood K, Masendycz PJ *et al.* (1990) Comparison of  
rotavirus immunoglobulin A coproconversion with other indices of rotavirus  
30 infection in a longitudinal study in childhood. *Journal of Clinical Microbiology* **28**:1367-74.
20. Goldwater PN. (1995) Immunoglobulin M capture immunoassay in  
investigation of coxsackievirus B5 and B6 outbreaks in South Australia.  
*Journal of Clinical Microbiology* **33**:1628-31.

21. Jones DB, Crosby I. (1996) Proliferative lymphocyte responses to virus antigens homologous to GAD65 in type 1 diabetes. *Diabetologia* 39: 1318-1324.
22. Cerrutti F, Urbino A, Sacchetti C, Palomba E, Zoppo M, Tovo PA.  
5 (1988) Selective IgA deficiency in juvenile-onset insulin-dependent diabetes mellitus. *Pediatrica Medica e Chirurgia*. 10:197-201.
23. Kapikian AZ, Chanock RM. Rotaviruses. In: Fields Virology. Raven Publishers Philadelphia 1996; ed Fields BN et al; pp1657-1708.
24. Honeyman MC, Stone NL, Coulson BS, Harrison LC, unpublished  
10 observations.
25. Good, P.I. Permutation tests: a practical guide to resampling methods for testing hypotheses (1994) New York: Springer Series in Statistics.
26. Honeyman MC, Brusic V, Stone NL, Harrison LC. (1998) Neural  
15 network-based prediction of candidate T-cell epitopes. *Nature Biotechnology* 16:966-9.
27. Rudy G, Stone N, Harrison L *et al*, (1995) Similar peptides from two  $\beta$ -cell autoantigens, proinsulin and GAD, stimulate T cells of individuals at risk for IDDM. *Mol Med* 1: 625-633.
28. Van Eden W, Anderton SM, Van der Zee R, Prakken BJ, Broeren CP,  
20 Wauben MH. (1996) (Altered) self peptides and the regulation of self reactivity in the peripheral T-cell pool. *Imm Rev* 149: 55-73.
29. Schloot NC, Roep BO, Wegmann DR, Yu L, Wang TB, Eisenbarth GS. (1997) T-cell reactivity to GAD65 peptide sequences shared with Coxsackie virus protein in recent-onset type 1 diabetes, post-onset type 1 diabetes  
25 patients and control subjects. *Diabetologia* 40: 332-338.
30. Kumar D, Gemayel NS, Deapen D *et al*. (1993) North-American twins with type 1 diabetes. Genetic, etiological, and clinical significance of disease concordance according to age, zygosity, and the interval after diagnosis of the first twin. *Diabetes* 42: 1351-1363.
- 30 31. Yoon JW, Austin M, Onodera T, Notkins AL. (1979) Virus-induced diabetes mellitus. Isolation of a virus from the pancreas of a child with diabetic ketoacidosis. *N Engl J Med* 300: 1173-1179.
32. Forrest JM, Menser MA, Burgess JA. (1971) High frequency of diabetes mellitus in young adults with congenital rubella. *Lancet* 2 (720): 332-334.

33. Karam JH, Lewitt PA, Young CW. (1980) Insulinopenic diabetes after rodenticide (Vacor) ingestion. A unique model of acquired diabetes in man. *Diabetes* 29: 971-978.
34. Foulis AK, McGill M, Farquharson MA, Hilton DA. (1997) A search  
5 for evidence of viral infection in pancreases of newly diagnosed patients with type 1 diabetes. *Diabetologia* 40: 53-61.
35. Harrison LC, McColl G. (1997) Infection and autoimmune disease. In: *The Autoimmune Diseases, second edition*. Rose NR, Mackay IR, Eds. San Diego, CA, Academic, Press pp. 127-140.
- 10 36. Atkinson MA, Bowman MA, Campbell L, Darrow BL, Kaufman DL, Maclaren NK. (1994) Cellular immunity to a determinant common to glutamate decarboxylase and coxsackie virus in insulin-dependent diabetes mellitus. *J Clin Invest* 94: 2125-2129.
37. Tian J, Lehmann PV, Kaufman DL. (1994) T cell cross-reactivity  
15 between coxsackievirus and glutamic acid decarboxylase is associated with a murine diabetes susceptibility allele. *J Exp Med* 180: 1979-1984.
38. Honeyman MC, Stone NL, Brusica V, Harrison LC. (1994) Identification of T-cell epitopes containing DR binding motifs in human glutamic acid decarboxylase (GAD). Proc 13th Int Imm and Diabetes Workshop,  
20 Montvillargenne, France p101
39. Endl J, Otto H, Jung G et al. (1997) Identification of naturally processed T cell epitopes from glutamic acid decarboxylase presented in the context of HLA-DR alleles by T lymphocytes of recent onset IDDM patients. *J Clin Invest* 99:2405-15.
- 25 40. Lohmann T, Leslie RD, Londei M. (1996) T cell clones to epitopes of glutamic acid decarboxylase 65 raised from normal subjects and patients with insulin-dependent diabetes. *J Autoimm* 9:385-9.
41. Dahlquist G, Frisk G, Ivarsson SA, Svanberg L, Forsgren M, Diderholm H. (1995) Indications that maternal coxsackie B virus infection during  
30 pregnancy is a risk factor for childhood-onset IDDM. *Diabetologia*. 38:1371-3.
42. Hiltunen M, Hyoty H, Karjalainen J et al. (1995) Serological evaluation of the role of cytomegalovirus in the pathogenesis of IDDM: a prospective study. The Childhood Diabetes in Finland Study Group. *Diabetologia*. 38:705-10.
- 35 43. Hiltunen M, Hyoty H, Knip M et al. (1997) Islet cell antibody seroconversion in children is temporally associated with enterovirus

- infections. Childhood Diabetes in Finland (DiMe) Study Group. *Journal of Infectious Diseases* 175:554-60.
44. Hyoty H, Hiltunen M, Knip M *et al.* Akerblom HK and Childhood Diabetes in Finland (DiMe) Study Group. (1995) A prospective study of the  
5 role of Coxsackie B and other enterovirus infections in the pathogenesis of type 1 diabetes. *Diabetes* 44: 652-657.
45. Brusic V, Rudy G, Kyne AP, Harrison LC. (1996) MHCPEP - a database of MHC-binding peptides: update 1995. *Nucleic Acids Res* 24: 242-244.
46. Kapikian AZ, Hoshino Y, Chanock RM, Perez-Schael I, (1996) Efficacy  
10 of a quadrivalent rhesus rotavirus-based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children. [Review] [39 Refs] *Journal of Infectious Diseases*. 174 Suppl 1:S65-72, Sep.
47. Patel SD, Cope AP, Congia M *et al.* (1997) Identification of immunodominant T cell epitopes of human glutamic acid decarboxylase  
15 by using HLA-DR(A1\*0101,B1\*0401) transgenic mice. *Proc Nat Acad Sci USA* 94: 8082-8087.
48. Heath R, Stagg S, Xu F, McCrae MA. (1997) Mapping of the target antigens of the rotavirus-specific cytotoxic T-cell response. *J Gen Virol* 78: 1065-1075.
- 20 49. Franco MA, Prieto I, Labbe M, Poncet D, Borrás-Cuesta F, Cohen J. (1993) An immunodominant cytotoxic T cell epitope on the VP7 rotavirus protein overlaps the H2 signal peptide. *Journal of General Virology* 74:2579-86.
50. Kapikian AZ, Chanock RM. Rotaviruses. (1996) In: *Fields Virology*.  
25 Raven Publishers Philadelphia; ed Fields BN *et al*;pp1657-1708.
51. Verge CF, Howard NJ, Irwig L, Simpson JM, Mackerras D, Silink M. (1994) Environmental factors in childhood IDDM. A population-based, case-control study. *Diabetes Care* 17: 1381-1389.
52. Gardner SG, Bingley PJ, Sawtell PA, Weeks S, Gale EA. (1997) Rising  
30 incidence of insulin dependent diabetes in children aged under 5 years in the Oxford region: time trend analysis. The Bart's-Oxford Study Group. *Brit Med J* 20;315:713-7.
53. Rott LS, Rose JR, Bass D, Williams MB, Greenberg HB, Butcher EC. (1997) Expression of mucosal homing receptor  $\alpha 4\beta 7$  by circulating  
35 CD4+ cells with memory for intestinal rotavirus. *J Clin Invest* 100: 1204-1208.

54. Paronen J, Klemetti P, Kantele JM *et al.* (1997) Glutamate decarboxylase-reactive peripheral blood lymphocytes from patients with IDDM express gut-specific homing receptor  $\alpha 4\beta 7$ -integrin. *Diabetes* **46**: 583-588.
- 5 55. Hanninen A, Salmi M, Simell O, Jalkanen S. (1996) Mucosa-associated (beta 7-integrin high) lymphocytes accumulate early in the pancreas of NOD mice and show aberrant recirculation behaviour. *Diabetes* **45**: 1173-1180.
56. Honeyman MC, Stone NL, Harrison LC. (1998) T-cell epitopes in type  
10 1 diabetes autoantigen tyrosine phosphatase IA-2: potential for mimicry with rotavirus and other environmental agents. *Molecular Medicine* **4**:231-9.
57. De La Rubia L, Herrera MI, Cebrero M, De Jong JC. (1996) Acute pancreatitis associated with rotavirus infection. *Pancreas* **12**:98-9.
58. Nigro G. (1991) Pancreatitis with hypoglycemia-associated  
15 convulsions following rotavirus gastroenteritis. *Journal of Pediatric Gastroenterology & Nutrition*. **12**:280-2.
59. Campbell IL, Harrison LC, Ashcroft RG, Jack I. (1988) Reovirus infection enhances expression of class I MHC proteins on human beta-cell and rat RINm5F cell. *Diabetes* **37**:362-5.
- 20 60. Onodera T, Jenson AB, Yoon JW, Notkins AL. (1978) Virus-induced diabetes mellitus: reovirus infection of pancreatic beta cells in mice. *Science*. **201**:529-31.
61. Cavallo MG, Fava D, Monetini L, Barone F, Pozzilli P. (1996) Cell-mediated immune response to beta casein in recent-onset  
25 insulin-dependent diabetes: implications for disease pathogenesis. *Lancet* **348**: 926-928.
62. Harrison LC, Honeyman M. (1999) Cow's milk and type 1 diabetes: the real debate is about mucosal immune function. *Diabetes* (in press).
63. Hoorfar J, Buschard K, Dagnaes-Hansen F. (1993) Prophylactic  
30 nutritional modification of the incidence of diabetes in autoimmune non-obese diabetic (NOD) mice. *Br J Nutrition* **69**: 597-607.



## CLAIMS:-

1. A tyrosine phosphatase IA-2 T-cell epitope, the T-cell epitope having a sequence included within or consisting of a sequence selected from the group consisting of ANMDISTGHMILAYME, WQALCAYQAEPNTCAT, PYDHARIKLKVESSPS, LSHTIADFWQMVWESG, DFWQMVWESGCTVIVM, WESGCTVIVMLTPLVE, VIVMLTPLVEDGVKQC, SEHIWCEDFLVRSFYL, WCEDFLVRSFYLKNVQ, EDFLVRSFYLKNVQTQ, DFRRKVNKCYRGRSCP, YILIDMVLNRMAKGVK, FEFALTAVAEVNAIL and conservative substitutions therein.
2. A tyrosine phosphatase IA-2 T-cell epitope as claimed in claim 1 in which the T-cell epitope has a sequence included within or consisting of a sequence selected from the group consisting of ANMDISTGHMILAYME, WQALCAYQAEPNTCAT, PYDHARIKLKVESSPS, LSHTIADFWQMVWESG, DFWQMVWESGCTVIVM, WESGCTVIVMLTPLVE, VIVMLTPLVEDGVKQC, SEHIWCEDFLVRSFYL, WCEDFLVRSFYLKNVQ, EDFLVRSFYLKNVQTQ, DFRRKVNKCYRGRSCP, YILIDMVLNRMAKGVK, and FEFALTAVAEVNAIL.
3. A tyrosine phosphatase IA-2 T-cell epitope as claimed in claim 1 or claim 2 in which the T-cell epitope has a sequence included within or consisting of the sequence VIVMLTPLVEDGVKQC.
4. A tyrosine phosphatase IA-2 T-cell epitope as claimed in any one of claims 1 to 3 in which the T-cell epitope has the sequence VIVMLTPLVED.
5. A T-cell epitope, the T-cell epitope having a sequence included within or consisting of a sequence selected from the group consisting of SNMDISTGHMILSYME, WEALCAYQAEPNSSFV, TYDHSRVLLKAENSHS, LPATVADFWQMVWESG, DFWQMVWESGCVVIVM, WESGCVVIVMLTPLAE, VIVMLTPLAENGVRQC, SEHIWCEDFLVRSFYL, WCEDFLVRSFYLKNLQ, EDFLVRSFYLKNLQTN, DFRRKVNKCYRGRSCP, YVLIDMVLNKMAGAK, FEFALTAVAEVNAIL and conservative substitutions therein.
6. A T-cell epitope as claimed in claim 5 in which the T-cell epitope has a sequence included within or consisting of a sequence selected from the group consisting of SNMDISTGHMILSYME, WEALCAYQAEPNSSFV, TYDHSRVLLKAENSHS, LPATVADFWQMVWESG, DFWQMVWESGCVVIVM, WESGCVVIVMLTPLAE, VIVMLTPLAENGVRQC,

SEHIWCEDFLVRSFYL, WCEDFLVRSFYLKNLQ, EDFLVRSFYLKNLQTN,  
DFRRKVNKCVRGRSCP, YVLIDMVLNKNMAKGAK, and  
FEFALTAVAEVNAI.

7. A method of assessing the risk of an individual developing type 1  
5 diabetes, the method comprising measuring responsiveness of T cells of the  
individual to at least one of the peptides as claimed in any one of claims 1 to  
6 and comparing the T-cell responses from the individual without the  
peptides, and in comparison to responses from healthy controls.
8. A method for the prevention or delay of the onset of type 1 diabetes in  
10 an individual, the method comprising administering at least one peptide as  
claimed in any one claims 1 to 6 to the individual to induce tolerance to the  
epitope.
9. A method as claimed in claim 8 in which the at least one peptide is  
administered to a mucosal surface of the subject.
- 15 10. A method as claimed in claim 9 in which the peptide is administered  
orally, by aerosol or intranasally.
11. A method of preventing or delaying the re-establishment of type 1  
diabetes in an individual who has received a pancreatic or islet-cell  
transplant, the method comprising administering at least one peptide as  
20 claimed in any one claims 1 to 6 to the individual to induce tolerance to the  
epitope.
12. A method as claimed in claim 11 in which the at least one peptide is  
administered to a mucosal surface of the subject.
13. A method as claimed in claim 12 in which the peptide is administered  
25 orally, by aerosol or intranasally.
14. A vaccine composition for use in raising an immune response in a  
subject directed against rotavirus, the composition comprising a plurality of  
antigens including at least one rotavirus VP7 antigen wherein the sequence  
of the rotavirus VP7 antigen is modified such that at least one of the  
30 sequences which mimic one or more of the epitopes selected from the group  
consisting of ILLQYVVKSFDRS, ILLNYVRKTFDRS and VIVMLTPLVED are  
deleted or modified such as to remove or ameliorate mimicry.
15. A vaccine composition as claimed in claim 14 in which the  
composition comprises at least one attenuated strain of rotavirus, the  
35 rotavirus nucleic acid encoding VP7 being modified such that the expressed  
VP7 antigen is modified such that at least one of the sequences which mimic

one or more of the epitopes selected from the group consisting of ILLQYVVKSF, ILLNYVRKTF and VIVMLTPLVED are deleted or modified such as to remove or ameliorate mimicry.

16. A vaccine composition as claimed in claim 14 or claim 15 in which the the sequence which mimics ILLQYVVKSF or ILLNYVRKTF is deleted.

17. A ligand for antigen-specific T lymphocytes, the ligand comprising a multimeric peptide-MHC complex in which the peptide is selected from the group consisting of ANMDISTGHMILAYME, WQALCAYQAEPNTCAT, PYDHARIKLVESSES, LSHTIADFWQMVWESG, DFWQMVWESGCTVIVM, WESGCTVIVMLTPLVE, VIVMLTPLVEDGVKQC, SEHIWCEDFLVRSFYLYL, WCEDFLVRSFYLYLKNVQ, EDLVRSFYLYLKNVQQTQ, DFRRKVNKCVRGRSCP, YILIDMVLNRMAKGVK, FEFALTAVAEVNAI, SNMDISTGHMILSYME, WEALCAYQAEPNSSFV, TYDHSRVLLKAENSHS, LPATVADFWQMVWESG, DFWQMVWESGCVVIVM, WESGCVVIVMLTPLAE, VIVMLTPLAENGVRQC, SEHIWCEDFLVRSFYLYL, WCEDFLVRSFYLYLKNLQ, EDLVRSFYLYLKNLQTN, DFRRKVNKCVRGRSCP, YVLIDMVLNKMAGKAK, FEFALTAVAEVNAI and conservative substitutions therein.

18. A ligand as claimed in claim 17 in which the peptide is VIVMLTPLVEDGVKQC or VIVMLTPLVED.

19. A ligand as claimed in claim 17 or 18 in which the multimer is a dimer or tetramer.

20. A ligand as claimed in any one of claims 17 to 20 in which the ligand is provided with a detectable label, such as biotin, a fluorophor, or radioisotope.

1/4

Figure 1

RQHARQQDKERLAALGPEGAGDITTFEYQDLCRQHMAKSLFNRAEGPPEPSRVSSVSQFSDAAQASPSSHSSTP  
 SWCEEPACANMDISTGHMILAYMEDHLNRDRLAKEWQALCAYQAEPTCATAQEGENIKKNRHPDFTPYDHARIK  
 LKVESSPRSYINASPIIEHDPRMPAYIATQGLSHTLADFQMWESGCIVVNLTPLVLDGVKQCDRYWPDEG  
 ASLYHVVEVNLVSEHIMCEDFLVRSFYIKNVQIQETRTLTFHFHLSWPAEGTPASTRPLIDFRRKVNKCYGRSCH  
 IIVHCSDGAGRTGIIYLIDMVLNRMAKGVKEIDIAATLEHVDRDQRPGLVRSKDDFEFALTAVAEVNAIILKALPQ

685 713 745 787 793 799 805 841 845-847 889 919 959

2/4




FIGURE 2

3/4




FIGURE 3




FIG. 4

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU 99/00314

## A. CLASSIFICATION OF SUBJECT MATTER

Int Cl<sup>6</sup>: C12N 9/12 C07K 7/00 A61K 39/15, 37/02

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

WPAT, Chemical Abstracts - See below<sup>6</sup>

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
Medline - See below

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
WPAT, Chemical Abstracts, Medline: protein tyrosine phosphatase, tyrosine protein phosphatase, tyrosine phosphatase, epitope, diabetes, 1A-2, VP7

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	Nature Biotechnology (1998, October) volume 16, pages 966-969 by Honeyman MC et al. "Neural network-based prediction of candidate T-cell epitopes". See entire document.	1-20
X	Molecular Medicine (1997) volume 29, pages 401-404 by Honeyman MC et al. "Strategies for identifying and predicting islet autoantigen T-cell epitopes in insulin-dependent diabetes mellitus". See entire document, in particular Methods section.	1-20
X	Molecular Medicine (1998, April) volume 4, pages 231-9 by Honeyman MC et al. "T-cell epitopes in type 1 diabetes autoantigen tyrosine phosphatase IA-2: potential for mimicry with rotavirus and other environmental agents". See entire document.	1-20

☒ Further documents are listed in the continuation of Box C

☐ See patent family annex

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance  
"E" earlier application or patent but published on or after the international filing date  
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  
"O" document referring to an oral disclosure, use, exhibition or other means  
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art  
"&" document member of the same patent family

Date of the actual completion of the international search  
10 June 1999

Date of mailing of the international search report  
22 JUN 1999

Name and mailing address of the ISA/AU  
AUSTRALIAN PATENT OFFICE  
PO BOX 200  
WODEN ACT 2606  
AUSTRALIA  
Facsimile No.: (02) 6285 3929

Authorized officer

  
JULIE CAIRNDUFF

Telephone No.: (02) 6283 2545



**INTERNATIONAL SEARCH REPORT**

International application No.

**PCT/AU 99/00314**

<b>C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
<b>Category*</b>	<b>Citation of document, with indication, where appropriate, of the relevant passages</b>	<b>Relevant to claim No.</b>
A	Diabetes (1997) volume 46, pages 40-43 by Zhang B et al. "Autoantigens to IA-2 in IDDM: location of major antigenic determinants". See entire document.	1-20
A	Journal of Immunology (1996) volume 157, pages 2707-2711 by Lampasona V et al. "Autoantibodies in Insulin-dependent diabetes recognize distinct cytoplasmic domains of the protein tyrosine phosphatase-like IA-2 autoantigen". See entire document.	1-20

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER: \_\_\_\_\_**

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**